Among transcription factor mutations in myeloid neoplasia, CEBPA and RUX1 mutations are deemed important by the WHO due to their prognostic implications. CCAAT Enhancer Binding Protein-alpha (CEBPA) is a transcription factor responsible for promoting granulocytic maturation in regulating cellular function. CEBPA mutations are observed in approximately 10% of de novo AML patients and are commonly bi-allelic. This evidence concerns the gene CEBPA and acute myeloid leukemia.